Thursday, February 21, 2013

• Study Casts Doubt On Value Of Genetic Testing For Familial Hypercholesterolemiaat Forbes (Thu, Feb 21)
• AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a MaterEDGAR Online (Thu, Feb 21)

Wednesday, February 20, 2013

• Aegerion Pharmaceuticals to Announce Fourth Quarter 2012 Financial Results on Wednesday, March 6GlobeNewswire (Wed, Feb 20)

Friday, February 15, 2013

• VIX - Options Volatility And Market Sonar: Friday Recapat Seeking Alpha (Fri, Feb 15)
• Bull doubles bet on Aegerion PharmaoptionMONSTER (Fri, Feb 15)

Sunday, February 10, 2013

• How Long Can This Pharma Gold Rush Last?at Motley Fool (Sun, Feb 10)

Monday, February 4, 2013

• Sanofi & Isis Out-Limbo Aegerion in HoFHat Motley Fool (Mon, Feb 4)

Saturday, February 2, 2013

• Aegerion Pharmaceuticals Expected To Take A Hitat Seeking Alpha (Sat, Feb 2)

Friday, February 1, 2013

• FDA Approved a Total of 39 New Drugs in 2012 -- Fifteen Year HighMarketwired (Fri, Feb 1)
• Who Will Win This Small Drug Market?at Motley Fool (Fri, Feb 1)
• Biotech Stock Mailbag: Celsion, Navidea, AP Pharma, Sareptaat TheStreet (Fri, Feb 1)

Thursday, January 31, 2013

• Isis Aces its Testat Motley Fool (Thu, Jan 31)
• Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion PharmaceuticalsZacks (Thu, Jan 31)

Wednesday, January 30, 2013

• Why Isis Pharmaceuticals Shares Poppedat Motley Fool (Wed, Jan 30)
• Isis Jumps as FDA Clears Cholesterol Treatmentat Bloomberg (Wed, Jan 30)
• US Nod for ISIS/Sanofi's KynamroZacks (Wed, Jan 30)
• Insider Siren: Should We Follow the “Whales” Into These Stocks?at Motley Fool (Wed, Jan 30)
• Genzyme, Aegerion approvals offer new leases on life for patientsat bizjournals.com (Wed, Jan 30)
• U.S. Stock Options With Biggest Changes in Implied Volatilityat Bloomberg (Wed, Jan 30)
• Isis Pharmaceuticals: A Compelling Long-Term Storyat Seeking Alpha (Wed, Jan 30)
• Isis and Sanofi's Drug OK'd to Treat Inherited Cholesterol Diseaseat Minyanville (Wed, Jan 30)
• Isis Pharmaceuticals: Kynamro's Approval Is An Antisense Home Run.at Seeking Alpha (Wed, Jan 30)
• Aegerion CEO Speaks On Juxtapid Launch, Orphan Drug Pricing And Competitionat TheStreet (Wed, Jan 30)

Tuesday, January 29, 2013

• FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemiaat Forbes (Tue, Jan 29)

Monday, January 28, 2013

• Amazon Expected to Report In-Line and 4 Stock Analyses to Trackat Wall St. Cheat Sheet (Mon, Jan 28)

Add AEGR News to My Yahoo!